{"id":"https://openalex.org/W3040239170","doi":"https://doi.org/10.1007/s40261-020-00941-3","title":"Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study","display_name":"Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study","publication_year":2020,"publication_date":"2020-07-03","ids":{"openalex":"https://openalex.org/W3040239170","doi":"https://doi.org/10.1007/s40261-020-00941-3","mag":"3040239170","pmid":"https://pubmed.ncbi.nlm.nih.gov/32621143","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7452866"},"language":"en","primary_location":{"id":"doi:10.1007/s40261-020-00941-3","doi":"https://doi.org/10.1007/s40261-020-00941-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-020-00941-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-020-00941-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40261-020-00941-3.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103136694","display_name":"Tomohiko Ishikawa","orcid":"https://orcid.org/0000-0003-3489-2695","observed_orcids":["https://orcid.org/0000-0003-3489-2695"]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Tomohiko Ishikawa","raw_affiliation_strings":["Medical Affairs Department, Fuji Yakuhin Co., Ltd., 9F Kanda Square Building, 2-2-1 Kandanishiki-cho, Chiyoda-ku, Tokyo, 101-8189, Japan. L2-80947@fujiyakuhin.co.jp","Medical Affairs Department, Fuji Yakuhin Co., Ltd., 9F Kanda Square Building, 2-2-1 Kandanishiki-cho, Chiyoda-ku, Tokyo, 101-8189, Japan"],"raw_orcid":"https://orcid.org/0000-0003-3489-2695","affiliations":[{"raw_affiliation_string":"Medical Affairs Department, Fuji Yakuhin Co., Ltd., 9F Kanda Square Building, 2-2-1 Kandanishiki-cho, Chiyoda-ku, Tokyo, 101-8189, Japan. L2-80947@fujiyakuhin.co.jp","institution_ids":["https://openalex.org/I4405266857"]},{"raw_affiliation_string":"Medical Affairs Department, Fuji Yakuhin Co., Ltd., 9F Kanda Square Building, 2-2-1 Kandanishiki-cho, Chiyoda-ku, Tokyo, 101-8189, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tatsushi Maeda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270935","display_name":"Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)","ror":"https://ror.org/01jrk5n74","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405270935"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tatsushi Maeda","raw_affiliation_strings":["Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan","institution_ids":["https://openalex.org/I4405270935"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Teruo Hashimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Teruo Hashimoto","raw_affiliation_strings":["Pharmacovigilance Department, Reliability and Quality Assurance Division, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance Department, Reliability and Quality Assurance Division, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tetsuya Nakagawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270935","display_name":"Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)","ror":"https://ror.org/01jrk5n74","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405270935"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsuya Nakagawa","raw_affiliation_strings":["Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan","institution_ids":["https://openalex.org/I4405270935"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kazuhito Ichikawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270935","display_name":"Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)","ror":"https://ror.org/01jrk5n74","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405270935"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuhito Ichikawa","raw_affiliation_strings":["Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance Department, Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan","institution_ids":["https://openalex.org/I4405270935"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021158752","display_name":"Yasushi Sato","orcid":"https://orcid.org/0000-0002-6776-4609","observed_orcids":["https://orcid.org/0000-0002-6776-4609","https://orcid.org/0000-0003-0446-8017"]},"institutions":[{"id":"https://openalex.org/I4405266857","display_name":"Fuji Yakuhin Co., Ltd. (Japan)","ror":"https://ror.org/0031t6k06","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405266857"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasushi Sato","raw_affiliation_strings":["Reliability and Quality Assurance Division, Fuji Yakuhin Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Reliability and Quality Assurance Division, Fuji Yakuhin Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I4405266857"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009044898","display_name":"Yoshihiko Kanno","orcid":"https://orcid.org/0000-0003-2481-2372","observed_orcids":["https://orcid.org/0000-0003-2481-2372"]},"institutions":[{"id":"https://openalex.org/I158929114","display_name":"Tokyo Medical University","ror":"https://ror.org/00k5j5c86","country_code":"JP","type":"education","lineage":["https://openalex.org/I158929114"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshihiko Kanno","raw_affiliation_strings":["Department of Nephrology, Tokyo Medical University, Shinjuku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Nephrology, Tokyo Medical University, Shinjuku, Tokyo, Japan","institution_ids":["https://openalex.org/I158929114"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5103136694"],"corresponding_institution_ids":["https://openalex.org/I4405266857"],"apc_list":{"value":3260,"currency":"USD","value_usd":3260},"apc_paid":{"value":3260,"currency":"USD","value_usd":3260},"fwci":2.36,"has_fulltext":true,"cited_by_count":36,"citation_normalized_percentile":{"value":0.89696736,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"40","issue":"9","first_page":"847","last_page":"859"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/topiroxostat","display_name":"topiroxostat","score":0.9980000257492065},{"id":"https://openalex.org/keywords/xanthine-oxidoreductase-inhibitors","display_name":"xanthine oxidoreductase inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/hyperuricemia","display_name":"hyperuricemia","score":0.9909999966621399},{"id":"https://openalex.org/keywords/gout","display_name":"gout","score":0.9980000257492065},{"id":"https://openalex.org/keywords/serum-uric-acid","display_name":"serum uric acid","score":0.7300000190734863},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9190000295639038},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.800000011920929},{"id":"https://openalex.org/keywords/skin-diseases","display_name":"skin diseases","score":0.824999988079071},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.8140000104904175},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6840000152587891}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9024906158447266},{"id":"https://openalex.org/C2780402116","wikidata":"https://www.wikidata.org/wiki/Q133087","display_name":"Gout","level":2,"score":0.8906155824661255},{"id":"https://openalex.org/C2779721657","wikidata":"https://www.wikidata.org/wiki/Q49970","display_name":"Hyperuricemia","level":3,"score":0.7799714803695679},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6378145217895508},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5458285808563232},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.4928024113178253},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.49151358008384705},{"id":"https://openalex.org/C2779881121","wikidata":"https://www.wikidata.org/wiki/Q105522","display_name":"Uric acid","level":2,"score":0.4576221704483032},{"id":"https://openalex.org/C2780261098","wikidata":"https://www.wikidata.org/wiki/Q412486","display_name":"Allopurinol","level":2,"score":0.4212762713432312},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35947901010513306},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3475821018218994},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3317807912826538},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006073","descriptor_name":"Gout","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006074","descriptor_name":"Gout Suppressants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006074","descriptor_name":"Gout Suppressants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014527","descriptor_name":"Uric Acid","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014968","descriptor_name":"Xanthine Dehydrogenase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D033461","descriptor_name":"Hyperuricemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40261-020-00941-3","doi":"https://doi.org/10.1007/s40261-020-00941-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-020-00941-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-020-00941-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},{"id":"pmid:32621143","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32621143","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical drug investigation","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7452866","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7452866/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Drug Investig","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s40261-020-00941-3","doi":"https://doi.org/10.1007/s40261-020-00941-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-020-00941-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-020-00941-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3040239170.pdf","grobid_xml":"https://content.openalex.org/works/W3040239170.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W2030072500","https://openalex.org/W2031118520","https://openalex.org/W2047276432","https://openalex.org/W2050690746","https://openalex.org/W2082358169","https://openalex.org/W2111255580","https://openalex.org/W2114104370","https://openalex.org/W2114365596","https://openalex.org/W2130940048","https://openalex.org/W2254546342","https://openalex.org/W2335302945","https://openalex.org/W2336549647","https://openalex.org/W2345129305","https://openalex.org/W2346368478","https://openalex.org/W2518302708","https://openalex.org/W2549211436","https://openalex.org/W2761836300","https://openalex.org/W2789891715","https://openalex.org/W2888949772","https://openalex.org/W2889919904","https://openalex.org/W2941542476","https://openalex.org/W3145257564"],"related_works":["https://openalex.org/W2889919904","https://openalex.org/W2753652553","https://openalex.org/W2336549647","https://openalex.org/W2549211436","https://openalex.org/W4285411576","https://openalex.org/W2345129305","https://openalex.org/W3010819654","https://openalex.org/W4285244108","https://openalex.org/W4200256089","https://openalex.org/W2111255580"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,70],"OBJECTIVES:":[2],"Topiroxostat,":[3],"a":[4,62,164,238],"selective":[5],"xanthine":[6],"oxidoreductase":[7],"inhibitor,":[8],"is":[9,55,217],"used":[10],"for":[11,31,101,106,188,230],"the":[12,27,32,41,48,118,176,184,226],"management":[13],"of":[14,29,34,45,80,111,121,125,135,149,228],"hyperuricemic":[15,231],"patients":[16,82,98,105,232],"with":[17,36,233],"or":[18,37,225,234],"without":[19,38,235],"gout":[20,236],"in":[21,47,138,237,241],"Japan.":[22,242],"Accumulating":[23],"evidence":[24],"has":[25],"demonstrated":[26],"efficacy":[28,44,227],"topiroxostat":[30,46,229],"treatment":[33],"hyperuricemia":[35],"gout.":[39],"However,":[40],"safety":[42,102],"and":[43,53,76,88,103,117,130,144,162,174,201,208],"clinical":[49,58],"setting":[50,240],"remain":[51],"unclear,":[52],"there":[54,216],"little":[56],"large-scale":[57],"evidence.":[59],"We":[60],"conducted":[61],"post-marketing":[63,239],"observational":[64],"study":[65,213],"over":[66,160],"54":[67,169,202],"weeks.":[68],"PATIENTS":[69],"METHODS:":[71],"Patients":[72],"were":[73,83,99,141,206],"centrally":[74],"enrolled,":[75],"case":[77,148],"report":[78],"forms":[79],"4491":[81],"collected":[84],"between":[85],"April":[86],"2014":[87],"March":[89],"2019":[90],"from":[91],"825":[92],"medical":[93],"sites.":[94],"RESULTS:":[95],"Overall,":[96],"4329":[97],"assessed":[100],"4253":[104],"effectiveness.":[107],"The":[108,186],"overall":[109],"incidence":[110,119],"adverse":[112,122,222],"drug":[113,123,223],"reactions":[114,124,224],"was":[115,153],"6.95%,":[116],"rates":[120,187],"gouty":[126,151],"arthritis,":[127],"hepatic":[128],"dysfunction,":[129],"skin":[131],"disorders,":[132],"which":[133],"are":[134],"special":[136],"interest":[137],"this":[139],"study,":[140],"0.79%,":[142],"1.73%,":[143],"0.95%,":[145],"respectively.":[146,210],"No":[147],"serious":[150],"arthritis":[152],"observed.":[154],"Serum":[155],"urate":[156],"levels":[157,195],"decreased":[158],"stably":[159],"time":[161],"showed":[163],"significant":[165],"reduction":[166],"rate":[167],"at":[168,199],"weeks":[170,203],"(21.19%":[171],"\u00b1":[172,180],"22.07%)":[173],"on":[175],"final":[177],"visit":[178],"(19.91%":[179],"23.35%)":[181],"compared":[182],"to":[183],"baseline.":[185],"subjects":[189],"who":[190],"achieved":[191],"serum":[192],"uric":[193],"acid":[194],"\u2264":[196],"6.0":[197],"mg/dL":[198],"18":[200],"after":[204],"administration":[205],"43.80%":[207],"48.28%,":[209],"CONCLUSIONS:":[211],"This":[212],"suggests":[214],"that":[215],"no":[218],"particular":[219],"concern":[220],"about":[221]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":7},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2020-07-10T00:00:00"}